LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Начало・Списък с акции・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Затворен

СекторЗдравеопазване

13.48 -1.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

13.12

Максимум

13.81

Ключови измерители
By Trading Economics
Приходи	6.8M -12M
Продажби	3.5M 19M
Марж на печалбата	-64.131
Служители	120
EBITDA	7.4M -7.6M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+41.92% upside

Дивиденти
By Dow Jones
Следващи печалби	11.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	20M 421M
Предишно отваряне	14.8
Предишно затваряне	13.48

Настроения в новините

By Acuity

75%

25%

324 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

5.04 / 5.44 Подкрепа & съпротива

ENANTA PHARMACEUTICALS INC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.03.2026 г., 19:32 ч. UTC

Придобивния, сливания и поглъщания

Diana Shipping Increases Offer to Acquire Genco -- Update

6.03.2026 г., 17:44 ч. UTC

Придобивния, сливания и поглъщания

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6.03.2026 г., 22:26 ч. UTC

Значими събития в новините

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6.03.2026 г., 22:07 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6.03.2026 г., 22:03 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

6.03.2026 г., 22:03 ч. UTC

Пазарно говорене

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Financial Services Roundup: Market Talk

6.03.2026 г., 21:37 ч. UTC

Печалби

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6.03.2026 г., 21:25 ч. UTC

Значими събития в новините

How The Iran War Impacts Ukraine. -- Barrons.com

6.03.2026 г., 21:17 ч. UTC

Печалби

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6.03.2026 г., 20:50 ч. UTC

Печалби

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6.03.2026 г., 20:46 ч. UTC

Печалби

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6.03.2026 г., 20:31 ч. UTC

Значими събития в новините

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6.03.2026 г., 20:18 ч. UTC

Пазарно говорене

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6.03.2026 г., 20:12 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6.03.2026 г., 19:10 ч. UTC

Пазарно говорене

Значими събития в новините

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6.03.2026 г., 18:54 ч. UTC

Пазарно говорене

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6.03.2026 г., 18:44 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6.03.2026 г., 18:08 ч. UTC

Печалби

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6.03.2026 г., 18:04 ч. UTC

Печалби

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6.03.2026 г., 18:04 ч. UTC

Печалби

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6.03.2026 г., 17:49 ч. UTC

Пазарно говорене

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6.03.2026 г., 17:46 ч. UTC

Значими събития в новините

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6.03.2026 г., 17:40 ч. UTC

Пазарно говорене

Печалби

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6.03.2026 г., 17:40 ч. UTC

Печалби

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6.03.2026 г., 17:32 ч. UTC

Пазарно говорене

Значими събития в новините

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6.03.2026 г., 17:28 ч. UTC

Пазарно говорене

Значими събития в новините

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6.03.2026 г., 17:20 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

6.03.2026 г., 17:20 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

6.03.2026 г., 17:20 ч. UTC

Придобивния, сливания и поглъщания

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Сравнение с други в отрасъла

Ценова промяна

ENANTA PHARMACEUTICALS INC Прогноза

Ценова цел

By TipRanks

41.92% нагоре

12-месечна прогноза

Среден 19.5 USD 41.92%

Висок 20 USD

Нисък 19 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за ENANTA PHARMACEUTICALS INC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на ENANTA PHARMACEUTICALS INC през последните 3 месеца.

Техническа оценка

By Trading Central

5.04 / 5.44Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There are no events.

Настроение

By Acuity

324 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.